EUVIMEDEUVIMED entdecken
Crossref

Sphingolipid modulation and anti-tumor activity of Jaspine B in HepG2 bearing mice

Jihoon Lee, Ji-Hyeon Jeon, Minyeong Pang, Min-Koo Choi, Dongjoo Lee, Im-Sook Song

Archives of Pharmacal Research · 2025

DOI: 10.1007/s12272-025-01554-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Pharmacal Research, 2025. Verfasst von Jihoon Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80 Daehakro, Dae-gu, 41566, Republic of Korea. Hauptthemen laut MEDLINE: Sphingosine, Sphingolipids, Antineoplastic Agents, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cytotoxicity of Jaspine B was evaluated across a concentration range of 0.5-50 μM, yielding a half maximal inhibitory concentration (IC50) of 2.6 μM for HepG2 human hepatocellular carcinoma cells. To explore the mechanisms of Jaspine B, we investigated the expression of sphingosine kinase 1 (SphK1), a rate-limiting enzyme involved in the production of sphingosine-1-phosphate (S1P) from sphingosine, and the modulation of sphingolipids in HepG2 cells. Jaspine B reduced SphK1 expression and S1P levels in a dose-dependent manner. Additionally, flow cytometry analysis indicated that Jaspine B induces apoptosis in HepG2. In HepG2-xenografted mice, Jaspine B treatment (20 mg/kg/every other day for four weeks) reduced tumor size without significant changes in either body or organ weight. The anti-cancer effect in these mice was linked to reduced SphK1 expression in tumor tissue and lower plasma S1P levels. The concentration of Jaspine B in tumor tissue was 4.64 ± 2.05 μM, which exceeded its IC50 value (2.6 μM for cytotoxicity and 1.4 μM for SphK1 inhibition), further supporting its efficacy through SphK1inhibition. The anti-cancer effect and reduced plasma S1P levels induced by Jaspine B were comparable to PF543, a selective SphK1 inhibitor, in HepG2-xenografted mice. In conclusion, this study provides in vitro and in vivo evidence that Jaspine B is a promising anti-cancer agent for hepatocellular carcinoma, acting through SphK1 inhibition, with favorable pharmacokinetic and tumor distribution properties. This study also suggested that reduced plasma S1P levels may serve as a therapeutic biomarker for SphK1 inhibitors in hepatocellular carcinoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SphingosineSphingolipidsAntineoplastic AgentsLiver NeoplasmsCarcinoma, HepatocellularAnimalsHumansHep G2 CellsMicePhosphotransferases (Alcohol Group Acceptor)Dose-Response Relationship, DrugApoptosisMice, NudeXenograft Model Antitumor AssaysMaleMice, Inbred BALB CCell ProliferationLysophospholipidsSphingosine Kinase

Stichwörter der Autor:innen

HepG2 hepatocellular carcinomaJaspine BSphingosine kinase 1 (SphK1) inhibitorSphingosine-1-phopshate (S1P)

Substanzen

SphingosineSphingolipidsPhosphotransferases (Alcohol Group Acceptor)Antineoplastic AgentsLysophospholipidsSphingosine Kinasepachastrissaminesphingosine 1-phosphate

Autor:innen und Institutionen

  • College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80 Daehakro, Dae-gu, 41566, Republic of Korea.
  • BK21 FOUR Community‑Based Intelligent Novel Drug Discovery Education Unit and Vessel‑Organ Interaction Research Center (VOICE), Kyungpook National University, Daegu, 41566, Republic of Korea.
  • College of Pharmacy, Dankook University, Cheon-an, 31116, Republic of Korea.
  • College of Pharmacy and Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Suwon, 16499, Republic of Korea. dongjoo@ajou.ac.kr.
  • College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80 Daehakro, Dae-gu, 41566, Republic of Korea. isssong@knu.ac.kr.
  • BK21 FOUR Community‑Based Intelligent Novel Drug Discovery Education Unit and Vessel‑Organ Interaction Research Center (VOICE), Kyungpook National University, Daegu, 41566, Republic of Korea. isssong@knu.ac.kr.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Lee, J., Jeon, J. H., Pang, M., Choi, M. K., Lee, D., & Song, I. S. (2025). Sphingolipid modulation and anti-tumor activity of Jaspine B in HepG2 bearing mice. Archives of Pharmacal Research. https://doi.org/10.1007/s12272-025-01554-0

Vancouver

Lee J, Jeon JH, Pang M, Choi MK, Lee D, Song IS. Sphingolipid modulation and anti-tumor activity of Jaspine B in HepG2 bearing mice. Archives of Pharmacal Research. 2025. doi:10.1007/s12272-025-01554-0

BibTeX
@article{Lee2025,
  author = {Lee, Jihoon and Jeon, Ji-Hyeon and Pang, Minyeong and Choi, Min-Koo and Lee, Dongjoo and Song, Im-Sook},
  title = {Sphingolipid modulation and anti-tumor activity of Jaspine B in HepG2 bearing mice},
  journal = {Archives of Pharmacal Research},
  year = {2025},
  doi = {10.1007/s12272-025-01554-0}
}
Kostenlos starten →